Incannex Healthcare Inc.

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel oral fixed-dose combination treatments and therapeutic regimens. The company's mission is to create and commercialize innovative therapies for persistent and underserved medical conditions where existing treatments are either inadequate or carry significant drawbacks. Headquartered in Melbourne, Australia, Incannex Healthcare is expanding its global presence, particularly in the U.S. market.

Incannex focuses on a pipeline of combination therapies, primarily utilizing cannabinoid and psychedelic medicines. Key product candidates include IHL-42X, an oral fixed-dose combination for obstructive sleep apnea (OSA); PSX-001, an oral synthetic psilocybin treatment administered with psychological support for generalized anxiety disorder (GAD); and IHL-675A, an oral fixed-dose combination drug for inflammatory conditions such as rheumatoid arthritis (RA), inflammatory bowel disease, and lung inflammation. The company's approach involves pairing synthetic cannabinoids with other active drug components or psilocybin with psychological support to address chronic conditions with unmet medical needs.

Led by President and CEO Joel Latham, Incannex Healthcare has recently achieved several notable milestones. In March 2026, the company regained compliance with Nasdaq's minimum bid price requirement and reactivated its share repurchase program. The PSX-001 program for generalized anxiety disorder aligned with a White House Executive Order accelerating access to psychedelic treatments in April 2026. Incannex also reported a strong balance sheet with approximately $75 million in cash and no debt in March 2026, following positive Phase 2 outcomes for its lead candidate IHL-42X, which led to a strengthened clinical development pathway.